Skip to main content
Premium Trial:

Request an Annual Quote

ABI, HTS Biosystems, Mitsubishi Chemical in SPR Distribution Agreement

NEW YORK, April 7 - Applied Biosystems, HTS Biosystems, and Mitsubishi Chemical today announced a distribution agreement for a next-generation surface-plasmon resonance (SPR) system currently under development at HTS.

 

Under the agreement, Applied Biosystems Japan, a division of ABI, will be the exclusive distributor of the SPR system, which is designed to profile and characterize biomolecular interactions. The three companies also plan to co-develop new applications for the system, which ABI is targeting for worldwide commercial release by the mid-2003.

 

In 2000, HTS Biosystems granted Mitsubishi Chemical rights to distribute the SPR system once commercialized in Japan; and in April 2002, HTS and ABI entered a licensing and supply agreement to develop and commercialize the technology. Under the new agreement, HTS and Mitsubishi Chemical have granted ABI Japan exclusive distribution rights.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.